glp-1 masld Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study GLP-1RAs improve ALT in pediatric

It has the longer safety record with cardiovascular outcomes data now extending beyond 5 years and is widely available

However, like any medication, GLP-1 medications can sometimes cause side effects that may impact individuals' experiences with treatment

Packer M, Zile MR, Kramer CM, Baum SJ, Litwin SE, Menon V, et al

TRIUMPH-4: knee osteoarthritis plus obesity, the trial reported in December 2025

Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials

Preliminary studies have suggested that GLP-1 drugs might protect against or treat dementia and Alzheimers disease